Physician profile
Alan L Mitchell
NPI 1770500241
$2,807.50
in general payments reported to CMS, 2019-2025
26 companies · $303 in 2025
The $303 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $141 · 2021: $858 · 2022: $454 · 2023: $374 · 2024: $382 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $959 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $959.18 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $878.33 | 2021-2025 | Acthar |
| Allergan, INC. | $449.76 | 2019-2022 | |
| Horizon Therapeutics Plc | $168.34 | 2021-2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $135.82 | 2019-2025 | Cequa |
| Galderma Laboratories, L.P. | $133.19 | 2019-2023 | |
| Alcon Vision LLC | $119.02 | 2019-2025 | Tryptyr |
| Abbvie INC. | $106.71 | 2023-2025 | |
| Sight Sciences, INC. | $97.06 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Ani Pharmaceuticals, INC. | $90.77 | 2023-2024 | Purified Cortrophin Gel |
| Coopervision INC. | $62.56 | 2023-2024 | Myday Contact Lens |
| Kala Pharmaceuticals, INC. | $59.79 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $58.53 | 2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $53.65 | 2022-2025 | Scoutpro Osmolarity System, Doctors Allergy Formula |
| Johnson & Johnson Surgical Vision, INC. | $50.07 | 2021-2022 | |
| Eyevance Pharmaceuticals LLC | $45.25 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $43.99 | 2019-2021 | |
| Ocular Therapeutix, INC. | $40.55 | 2020-2021 | |
| Amgen INC. | $35.85 | 2024-2025 | Tepezza |
| Oyster Point Pharma, INC. | $33.66 | 2022-2023 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $30.19 | 2019-2021 | |
| Harrow Eye, LLC | $29.81 | 2025 | Vevye |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Shire North American Group INC | $18.93 | 2019 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $14.52 | 2023 | Acuvue |
| Biotissue Holdings INC. | $14.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.